Why is there a demand for platinum from the medical industry?
*In platinuminvestment.com, June 13, 2019
”How Platinum Treats Cancer
The introduction of the first platinum-based anti-cancer drug, cisplatin, in 1978 revolutionised the treatment of certain cancers. According to Cancer Research UK, cisplatin has been especially successful in the treatment of testicular cancer, and today, with surgery and combination chemotherapy treatment, there is a cure rate approaching 100 per cent for this disease.
Cisplatin is a platinum compound and, when administered through an intravenous injection directly into the blood stream, it works by interacting with DNA to destroy cancer cells and prevent them from multiplying.
The ability of platinum compounds to kill off cancer cells was an accidental discovery. In 1965, US biochemist Barnett Rosenberg conducted research into the effects of an electrical field on bacterial growth. Inexplicably, the bacteria cells responded by failing to divide and dying off.
Initially, Rosenberg thought this was because of the effects of the electrical field, but further investigation led to the conclusion that the platinum electrodes used to create the electric circuit were themselves reacting with the test solution. This reaction created a platinum compound that was, in fact, responsible for killing the cells.
Building on this knowledge, scientists found that cancer cells behaved in a similar way – the platinum compound causing them to die off. From here, several years of intense research led to the development of cisplatin, selected from a range of possible molecular combinations to create an optimal compromise between toxicity and efficacy, which began clinical trials in the UK in 1971.
Cisplatin, with a 65 per cent platinum content, has well known side effects and certain cancers can develop a resistance to it. Despite these drawbacks, it is still a front-line cancer treatment, although additional platinum-based therapies have since been developed to mitigate against these issues. Carboplatin, containing 52.5 per cent platinum, was approved in 1986 and is used mainly to treat ovarian and lung cancers. Available since 1996, Oxaliplatin with 49 per cent platinum is used to treat colorectal cancer.”
*This information is solely an excerpt of a third-party publication and is incomplete. Please subscribe to the referenced publication for the full article. This is not an offer to buy or sell precious metals. Investors should obtain advice based on their own individual circumstances and understand the risk before making any investment decision.